Supplementary Table S2 from Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery

Kathy S. Albain, Christina Yau, Emanuel F. Petricoin, Denise M. Wolf, Julie E. Lang, A. Jo Chien, Tufia C. Haddad, Andres Forero-Torres, Anne M. Wallace, Henry G. Kaplan, Lajos Pusztai, David Euhus, Rita Nanda, Anthony Elias, Amy S. Clark, Constantine Godellas, Judy C. Boughey, Claudine Isaacs, Debu Tripathy, Janice Lu, Rachel L. Yung, Rosa I. Gallagher, Julia Wulfkuhle, Lamorna Brown Swigart, Gregor Krings, Yunn‐Yi Chen, David A. Potter, Erica Stringer-Reasor, Sarah L. Blair, Smita Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Meredith Buxton, Julia L. Clennell, Ashish Sanil, Scott Berry, Adam L. Asare, Jeffrey B. Matthews, Angela DeMichele, Nola M. Hylton, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, W. Fraser Symmans, Laura J. van’t Veer, Douglas Yee, Donald A. Berry, Laura J. Esserman